[{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"HBV immunogen","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hookipa Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"HB-101","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hookipa Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"HB-202","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"HB-201","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"HB-202","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"HB-101","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hookipa Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"HB-201","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"HB-201","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"HB-201","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"HB-201","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"HB-200","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hookipa Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Arenavirus-based Vector","moa":"CD8+ T Cell","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hookipa Pharma","amount2":0.40999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"Hookipa Pharma \/ Gilead","highestDevelopmentStatusID":"4","companyTruncated":"Hookipa Pharma \/ Gilead"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"HB-201","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"HB-200","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hookipa Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"HB-200","moa":"KRAS G12C covalent","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"HB-300","moa":"PAP\/PSA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hookipa Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"HB-400","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hookipa Pharma","amount2":0.40999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"Hookipa Pharma \/ Gilead","highestDevelopmentStatusID":"4","companyTruncated":"Hookipa Pharma \/ Gilead"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"HB-700","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hookipa Pharma","amount2":0.95999999999999996,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.95999999999999996,"dosageForm":"","sponsorNew":"Hookipa Pharma \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"4","companyTruncated":"Hookipa Pharma \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"HB-700","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hookipa Pharma","amount2":0.95999999999999996,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.95999999999999996,"dosageForm":"","sponsorNew":"Hookipa Pharma \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"4","companyTruncated":"Hookipa Pharma \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"GS-2829","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Hookipa Pharma \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Hookipa Pharma \/ Gilead Sciences"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"HB-200","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hookipa Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"HB-500","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Hookipa Pharma \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Hookipa Pharma \/ Gilead Sciences"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Financing","leadProduct":"HB-500","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Hookipa Pharma","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"","sponsorNew":"Hookipa Pharma \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Hookipa Pharma \/ Gilead Sciences"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"HB-700","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hookipa Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"HB-200","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hookipa Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"HB-500","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Hookipa Pharma \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Hookipa Pharma \/ Gilead Sciences"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Eseba-vec","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hookipa Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Poolbeg Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2025","type":"Merger","leadProduct":"HB-700","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hookipa Pharma \/ HOOKIPA Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Hookipa Pharma \/ HOOKIPA Pharma"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"HB-500","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hookipa Pharma \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by Hookipa Pharma
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
